RxDoctor Payments Data

Raphael Lopez, MD

Internal Medicine · Alpharetta, GANPI 1932177177

Payments from drug & device makers

$8,847in general payments, 2019–2025

Across 555 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$932
  • Amgen$708
  • Boehringer Ingelheim$461
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,817100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,847 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$81,018
Medicare patients
266
Services billed
1,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$38,562
EliquisApixaban19$18,391
MounjaroTirzepatide14$16,910
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,413
PaxlovidNirmatrelvir/Ritonavir14$2,736
Potassium Chloride24$1,405
Atorvastatin Calcium130$1,354
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,200
Albuterol Sulfate HfaAlbuterol Sulfate42$950
ValacyclovirValacyclovir Hcl14$884
Levothyroxine Sodium59$752
Memantine Hcl24$656
Metoprolol Succinate29$638
Tamsulosin Hcl34$565
Escitalopram Oxalate39$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,034$38,56240 claims
PfizerEliquis, Paxlovid$280$21,12733 claims
Lilly USA, LLCMounjaro$932$16,91014 claims
GSKTrelegy Ellipta$324$8,41313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →